TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
Kappa Bioscience AS
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
287,210
|
216,263
|
206,355 |
| Financial expenses |
14,644
|
17,324
|
15,715 |
| Earnings before taxes |
106,716
|
74,728
|
47,546 |
| Total assets |
448,195
|
380,777
|
332,720 |
| Current assets |
177,531
|
140,256
|
151,714 |
| Current liabilities |
151,608
|
57,846
|
102,895 |
| Equity capital |
186,515
|
198,058
|
179,495 |
| - share capital |
958
|
1,008
|
1,074 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
41.6%
|
52.0%
|
53.9% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
37.2%
|
34.6%
|
23.0% |
| Return on assets (ROA) |
27.1%
|
24.2%
|
19.0% |
| Current ratio |
117.1%
|
242.5%
|
147.4% |
| Return on equity (ROE) |
57.2%
|
37.7%
|
26.5% |
| Change turnover |
81,804
|
22,588
|
42,411 |
| Change turnover % |
40%
|
12%
|
26% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.